Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTPRC-CYRIB fusion gene (lentiviral overexpression)
- Development stage
- Preclinical
- Lead developer
- Central South University
- Modality
- Gene Therapies
- Administration
- Intravenous, Intramuscular, Intraperitoneal, Intra-arterial, Intradermal, Subcutaneous, Intratumoral, Intralesional, Intrathecal, Percutaneous, Parenteral
01
Overview
PTPRC-CYRIB fusion gene (lentiviral overexpression) is an experimental genetic construct used to investigate the mechanisms of drug resistance in T-cell acute lymphoblastic leukemia (T-ALL). The PTPRC-CYRIB fusion gene was identified via next-generation sequencing in a patient with primary drug-resistant T-ALL and subsequently validated through molecular cloning. By overexpressing this fusion gene in T-ALL cell lines using a lentiviral vector, researchers demonstrated that it significantly increases cell proliferation rates and enhances clonogenic potential. Furthermore, overexpression of PTPRC-CYRIB has been shown to confer resistance to standard chemotherapeutic agents, including vincristine, idarubicin, cyclophosphamide, and prednisone, suggesting its role as a critical driver of chemoresistance in this leukemia subtype.
- Other names
- PTPRC-CYRIB overexpressionPTPRC-CYRIB OE
Beyond the preview
Go deeper on PTPRC-CYRIB fusion gene (lentiviral overexpression).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTPRC-CYRIB fusion gene (lentiviral overexpression).